Why Is Rhythm Pharma Stock Jumping Today?

Rhythm Pharmaceuticals (NASDAQ: RYTM) stock surged 5.47% after presenting six-month Phase 2 trial data for setmelanotide in Prader-Willi syndrome patients. The study showed meaningful improvements in BMI (3.06% mean reduction), body composition, hyperphagia, and behavioral measures, with a consistent safety profile. The trial enrolled 18 patients aged 6-23, with 17 remaining on active treatment.

06/15/2026, 12:51 PM • Benzinga

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

Rhythm Pharmaceuticals announced that seven presentations, including four late-breaking abstracts, have been accepted for The Endocrine Society's Annual Meeting (ENDO 2026) in Chicago from June 13-16, 2026. The presentations will showcase clinical trial data for setmelanotide and bivamelagon in treating rare neuroendocrine diseases including Prader-Willi syndrome, acquired hypothalamic obesity, and Bardet-Biedl syndrome. The company will also host its inaugural MOMENTUM meeting on June 12 to discuss advances in MC4R pathway diseases.

05/29/2026, 8:00 AM • GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals announced that its Chairman, President and CEO David Meeker and CFO Hunter Smith will participate in fireside chats at the Jefferies Global Healthcare Conference (June 4, 2026) and Goldman Sachs 47th Annual Global Healthcare Conference (June 8, 2026), respectively. The company's lead asset IMCIVREE (setmelanotide) is an FDA-approved MC4R agonist for treating rare obesity conditions including acquired hypothalamic obesity and genetic syndromes like Bardet-Biedl syndrome.

05/26/2026, 8:00 AM • GlobeNewswire

Green Thumb Just Made an Unprecedented Move. Here's What It Means for GTBIF Investors.

Green Thumb Industries has filed for DEA registration following the rescheduling of marijuana to Schedule III, positioning itself as a first-mover in the evolving U.S. cannabis landscape. The move could attract institutional investors, enable research partnerships, and potentially lead to major stock exchange listings if recreational cannabis is also rescheduled. CEO Ben Kovler emphasized that this strategic action normalizes the federal cannabis industry.

05/14/2026, 5:25 AM • The Motley Fool

Rhythm Pharmaceuticals Announces Changes to Board of Directors

Rhythm Pharmaceuticals announced the appointment of Kim Popovits, an accomplished life sciences leader with 40+ years of experience, to its Board of Directors, replacing departing board member Ed Mathers who served since 2013. Popovits brings extensive expertise in commercialization, reimbursement, and governance from her previous roles at Genomic Health and Genentech.

04/03/2026, 9:00 AM • GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity, becoming the first and only FDA-approved therapy for this rare disease. The approval is based on Phase 3 TRANSCEND trial results showing an 18.4% placebo-adjusted BMI reduction in 142 patients. The drug is indicated for adults and pediatric patients aged 4 years and older.

03/19/2026, 6:30 PM • GlobeNewswire

Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED)

U.S. stock futures declined on Tuesday following geopolitical tensions over the Strait of Hormuz, with major indices down 0.43-0.84%. European allies rejected Trump's call to deploy naval forces. Oil prices rose 4.72% amid supply concerns. Key movers included Uber (up on NVIDIA partnership), Lululemon (awaiting earnings), Cisco (down despite AI expansion), and Comtech (down 9.64% on mixed results). The Fed is expected to maintain rates unchanged in March.

03/17/2026, 8:33 AM • Benzinga

Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints

Rhythm Pharmaceuticals announced that its EMANATE Phase 3 trial for setmelanotide failed to meet primary endpoints for treating rare genetic obesity. While post hoc analyses showed statistically significant BMI reductions in specific patient subgroups and the safety profile remained consistent, the stock declined 4.98% to $86.00. The company plans to shift focus to next-generation MC4R agonists and continue analyzing the dataset.

03/17/2026, 7:12 AM • Benzinga

Stock Market Today: S&P 500, Dow Jones Futures Tumble As US Allies Reject Trump's Call To Deploy Navy At Hormuz—Uber, Lululemon, Cisco In Focus

U.S. stock futures declined on Tuesday following geopolitical tensions over the Strait of Hormuz, with major indices down 0.43-0.84%. European allies rejected Trump's call to deploy naval forces. Oil prices rose 4.72% amid supply concerns. Key movers included Uber (up on NVIDIA partnership), Lululemon (ahead of earnings), Comtech (down on mixed results), and Rhythm Pharmaceuticals (down on failed obesity drug trial). The Fed is expected to maintain rates unchanged in March.

03/17/2026, 5:28 AM • Benzinga

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced positive Phase 3 TRANSCEND trial data for setmelanotide in acquired hypothalamic obesity, showing an 18.8% placebo-adjusted BMI reduction difference across 142 patients at 52 weeks. The company's supplemental New Drug Application (sNDA) is under FDA review with a PDUFA goal date of March 20, 2026, and the company also plans regulatory submissions in Europe and Japan.

03/01/2026, 12:30 PM • GlobeNewswire

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharmaceuticals reported promising early Phase 2 trial results for setmelanotide in treating Prader-Willi syndrome, with potential therapeutic benefits in reducing BMI and extreme hunger. The company plans to advance to a Phase 3 trial and has initiated a new trial arm for a MC4R agonist.

12/11/2025, 1:17 PM • Benzinga

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Novo Nordisk are preparing to launch oral obesity treatment pills in 2026, with pricing expected to match existing injectable drugs, despite some underwhelming clinical trial data showing modest weight loss results.

08/19/2025, 2:28 PM • Benzinga